Issue 4, 2020

Adjuvant incorporated lipid nanoparticles for enhanced mRNA-mediated cancer immunotherapy

Abstract

For mRNA mediated cancer immunotherapy, Pam3 was incorporated as an adjuvant within lipid nanoparticles (LNPs) with OVA mRNA. The developed Pam3 incorporated LNPs showed successful expression of tumor antigens with enhanced immune stimulation. We demonstrated that the synergies of Pam3 LNPs could greatly improve the efficacy of tumor prevention by mRNA vaccines.

Graphical abstract: Adjuvant incorporated lipid nanoparticles for enhanced mRNA-mediated cancer immunotherapy

Supplementary files

Article information

Article type
Communication
Submitted
27 sep 2019
Accepted
19 nov 2019
First published
20 nov 2019

Biomater. Sci., 2020,8, 1101-1105

Adjuvant incorporated lipid nanoparticles for enhanced mRNA-mediated cancer immunotherapy

K. Lee, S. Y. Kim, Y. Seo, M. H. Kim, J. Chang and H. Lee, Biomater. Sci., 2020, 8, 1101 DOI: 10.1039/C9BM01564G

To request permission to reproduce material from this article, please go to the Copyright Clearance Center request page.

If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.

If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.

Read more about how to correctly acknowledge RSC content.

Social activity

Spotlight

Advertisements